Related Experiment Video
Updated: May 29, 2025
Isolation, Enrichment, and Maintenance of Medulloblastoma Stem Cells
Published on: September 1, 2010
Suppressing recurrence in Sonic Hedgehog subgroup medulloblastoma using the OLIG2 inhibitor CT-179
Yuchen Li1,2, Chaemin Lim3,4, Taylor Dismuke5
1QIMR Berghofer Medical Research Institute, Brisbane, QLD, 4006, Australia.
Abstract:
OLIG2-expressing tumor stem cells have been shown to drive recurrence in Sonic Hedgehog (SHH)-subgroup medulloblastoma (MB) and patients urgently need specific therapies to target this tumor cell population. Here, we investigate the therapeutic potential of the brain-penetrant orally bioavailable, OLIG2 inhibitor CT-179, using SHH-MB explant organoids, PDX and GEM SHH-MB models. We find that CT-179 disrupts OLIG2 dimerization, phosphorylation and DNA binding and alters tumor cell-cycle kinetics, increasing differentiation and apoptosis. CT-179 prolongs survival in SHH-MB PDX and GEM models and potentiates radiotherapy (RT) in vivo. Single cell transcriptomic studies (scRNA-seq) confirm that CT-179 increases differentiation and implicate Cdk4 up-regulation in maintaining proliferation during treatment. Consistent with CDK4 mediating CT-179 resistance, CT-179 combines effectively with the CDK4/6 inhibitor palbociclib, further prolonging survival in vivo. These data support therapeutic targeting of OLIG2+ tumor stem cells in regimens for SHH-driven MB, to improve response, delay recurrence and ultimately improve MB patient outcomes.
Insights
A new drug, CT-179, targets OLIG2+ tumor stem cells in Sonic Hedgehog medulloblastoma (SHH-MB). This approach disrupts tumor growth, enhances radiotherapy, and prolongs survival, offering hope for improved patient outcomes.
Area of Science:
- Neuro-oncology
- Cancer Stem Cell Biology
- Molecular Therapeutics
Background:
- Recurrence in Sonic Hedgehog (SHH)-subgroup medulloblastoma (MB) is driven by OLIG2-expressing tumor stem cells.
- There is an urgent need for targeted therapies against this specific tumor cell population in SHH-MB.
Purpose of the Study:
- To investigate the therapeutic potential of the OLIG2 inhibitor CT-179 in SHH-MB.
- To evaluate the efficacy of CT-179 alone and in combination with radiotherapy and CDK4/6 inhibitors.
Main Methods:
- Utilized SHH-MB organoid, patient-derived xenograft (PDX), and genetically engineered mouse (GEM) models.
- Assessed CT-179's effects on OLIG2 activity, cell-cycle kinetics, differentiation, and apoptosis.
- Employed single-cell transcriptomic studies (scRNA-seq) to analyze treatment response and resistance mechanisms.
- Evaluated combination therapy with palbociclib (a CDK4/6 inhibitor) and radiotherapy (RT).
Main Results:
- CT-179 disrupted OLIG2 dimerization, phosphorylation, and DNA binding, leading to increased tumor cell differentiation and apoptosis.
- CT-179 treatment prolonged survival in SHH-MB PDX and GEM models and potentiated the effects of radiotherapy.
- scRNA-seq identified Cdk4 up-regulation as a mechanism of resistance, which was overcome by combining CT-179 with palbociclib, further enhancing survival.
Conclusions:
- Targeting OLIG2+ tumor stem cells with CT-179 is a promising therapeutic strategy for SHH-driven MB.
- Combination therapy with CT-179, radiotherapy, and CDK4/6 inhibitors may improve treatment response and delay recurrence.
- These findings support the development of novel regimens to improve outcomes for MB patients.
